30 closest matches · ranked by relevance
Bronchiectasis
Primary: Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29). — -2.94; -0.32 log10 of CFU per gram sputum — p=< 0.001
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks — 336; NA; 186 Days — p=0.0650
Bronchiectasis
Primary: 24 Hour Sputum Volume — 41.8; 23.6; 29.9; 26.2 gram — p=<0.01
Bronchiectasis
Primary: Nontuberculous Mycobacterial (NTM) Disease — 188; 32 Events — p=0.19
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo — NA; NA Days — p=0.0511
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 7.4; 5.7 units on a scale — p=0.68
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 8.2; 3.2 units on a scale — p=0.011
Non-Cystic Fibrosis Bronchiectasis
Primary: Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period — NA; NA; 189.0 days — p== 0.014
Non-Cystic Fibrosis Bronchiectasis
Primary: Median Number of Exacerbations — 1; 2 exacerbations
Bronchiectasis With Acute Exacerbation
Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations
Bronchiectasis
Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115
Non-Cystic Fibrosis Bronchiectasis
Primary: Annualized Rate of Pulmonary Exacerbations (PEs) — 1.015; 1.036; 1.286 exacerbation per participant-year — p==0.0019
Cystic Fibrosis
Primary: Average Rate of Mucociliary Clearance (MCC) Over 60 Minutes — 14.8 percent cleared over 60 minutes — p=0.04
Cystic Fibrosis
Primary: Lung Function: Lung Clearance Index — 9; 9.7 lung clearance index
Cystic Fibrosis · Bronchiectasis
Primary: Occurrence of Any Treatment Emergent Adverse Events — 85.7; 93.3 Percentage of participants
Bronchiectasis
Primary: Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) at 8 Weeks — 60; 71; 84; 69 cmH2O — p=0.005
Bronchiectasis
Primary: Reliability of the Respiratory Domain of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) — 0.80 Intraclass Correlation Coefficient
Cystic Fibrosis
Primary: Time to an Exacerbation — 58; 51.5 Days — p=0.0715
Cystic Fibrosis
Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0-4 Hours (AUC0-4h) Response — 0.87; 2.51 Percent of predicted — p=0.092
Non-Cystic Fibrosis Bronchiectasis
Primary: Bacterial Clearance Rate of Sputum — 38; 16 Participants
Cystic Fibrosis (CF)
Primary: Change in P. Aeruginosa Density — 0.23; -0.31; -0.31; -0.73 log10 CFU/g sputum — p=0.0014
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 90; 180 participants
Sinusitis · Cystic Fibrosis
Primary: Computed Tomography Evidence of Less Sinus Disease — 5.875; 3 units on a scale — p=0.2
Non-cystic Fibrosis Bronchiectasis
Primary: Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs) — 6.80; 7.67; 6.10; 6.98 log10 CFUs
Non-cystic Fibrosis Bronchiectasis · Pseudomonas Aeruginosa · Lung Infection
Primary: P. Aeruginosa Recovery in Sputum Following Multiple Doses of AP-PA02 Administered by Inhalation — -0.5; -0.1; -0.4; 1.0 colony forming units log10
Cystic Fibrosis
Primary: The Number of Participants With Blood and Sputum Samples Collected — 18; 27; 0; 14 Participants
Bronchiectasis
Primary: The Ability of the Breath Test Model to Distinguish Bronchiectasis From Healthy People — 65; 67; 23 Participants — p=<0.05
Pulmonary Cystic Fibrosis
Primary: Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day — 13.30; 13.83 percentage change — p=0.0164
Bronchiectasis · Lung Disease · Respiratory Diseases
Primary: Ratio of Absolute Neutrophil Cell Count in Sputum at End of Treatment Compared to Baseline — 0.31; 1.00 ratio — p=0.004
Bronchiectasis
Primary: Ratio of Absolute Neutrophil Count at End of Treatment Compared to Baseline — 1.08; 1.01 ratio